Evidence map›Paper›PMID 33217190›Full record

ArticleCPT: pharmacometrics & systems pharmacology2020

Mechanisms of a Sustained Anti-inflammatory Drug Response in Alveolar Macrophages Unraveled with Mathematical Modeling.

Elin Nyman, Maria Lindh, William Lövfors, Christian Simonsson, Alexander Persson, Daniel Eklund, Erica Bäckström, Markus Fridén, Gunnar Cedersund

Open access · goldAbstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Elin NymanDepartment of Biomedical Engineering, Linköping University, Linköping, Sweden.
Maria LindhDrug Metabolism and Pharmacokinetics, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
William LövforsDepartment of Biomedical Engineering, Linköping University, Linköping, Sweden.
Christian SimonssonDepartment of Biomedical Engineering, Linköping University, Linköping, Sweden.
Alexander PerssonSchool of Medical Sciences, Faculty of Medicine and Health, Inflammatory Response and Infections Susceptibility Centre, Örebro University, Örebro, Sweden.
Daniel EklundSchool of Medical Sciences, Faculty of Medicine and Health, Inflammatory Response and Infections Susceptibility Centre, Örebro University, Örebro, Sweden.
Erica BäckströmDrug Metabolism and Pharmacokinetics, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Markus FridénDrug Metabolism and Pharmacokinetics, Early Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Gunnar CedersundDepartment of Biomedical Engineering, Linköping University, Linköping, Sweden.
Linköping University · SEAstraZeneca (Sweden) · SEÖrebro University · SEUppsala University · SE

Funding

CENIITHeart and Lung FoundationKAW and SciLifeLab Covid-19 platformSwedish Research Council Dnr 2019-03767
6 · The paper itself

Abstract

Both initiation and suppression of inflammation are hallmarks of the immune response. If not balanced, the inflammation may cause extensive tissue damage, which is associated with common diseases, e.g., asthma and atherosclerosis. Anti-inflammatory drugs come with side effects that may be aggravated by high and fluctuating drug concentrations. To remedy this, an anti-inflammatory drug should have an appropriate pharmacokinetic half-life or better still, a sustained anti-inflammatory drug response. However, we still lack a quantitative mechanistic understanding of such sustained effects. Here, we study the anti-inflammatory response to a common glucocorticoid drug, dexamethasone. We find a sustained response 22 hours after drug removal. With hypothesis testing using mathematical modeling, we unravel the underlying mechanism-a slow release of dexamethasone from the receptor-drug complex. The developed model is in agreement with time-resolved training and testing data and is used to simulate hypothetical treatment schemes. This work opens up for a more knowledge-driven drug development to find sustained anti-inflammatory responses and fewer side effects.

Indexed as

Models, BiologicalAnimalsAnti-Inflammatory AgentsDexamethasoneInflammationMacrophages, AlveolarRatsAnti-Inflammatory AgentsDexamethasone

Identifiers

PMID33217190
PMCPMC7762867
OpenAlexW3101242599

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.